Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Spreading the wealth

Buyside Europe

Spreading the wealth

OXFORD - Not everyone is entirely happy with the current U.S. biotech fizz. Anthony Milford of Framlington Health Fund in London prefers to invest in biotech stocks when they are both out of vogue and inexpensive. "Last year we saw U.S. small cap companies emulating if not outperforming the top tier biotech companies. Now it is difficult to find sound U.S. biotech stocks that have not already shown a good return," he said.

Consequently, Milford expects he will reduce his weighting in U.S. stocks - they have traditionally accounted for about 80 percent of his biotech

Read the full 981 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE